John Jesitus

John Jesitus is a medical writer based in Westminster, CO.

Articles by John Jesitus

In the quest for new vaccines, developers must balance clinical promise with practical concerns, said Kenneth Tomecki, M.D., at the 70th annual meeting of the American Academy of Dermatology. "The future for vaccines is very encouraging," says Dr. Tomecki, vice chairman, department of dermatology, Cleveland Clinic.

The safety and versatility of photodynamic therapy (PDT) make it a worthwhile addition for dermatologists not yet providing this treatment, according to Amy Forman Taub, M.D., who spoke at the 2011 annual meeting of the American Society of Cosmetic Dermatology and Aesthetic Surgery.

Newer drugs are available to combat potentially serious infections including methicillin-resistant Staphylococcus aureus (MRSA), says Kenneth J. Tomecki, M.D., vice-chairman, department of dermatology, Cleveland Clinic. Colonization, mainly of the anterior nares, remains a major risk factor for MRSA.

"A new microwave-based device is achieving long-lasting results in treating hyperhidrosis, said Suzanne L. Kilmer, M.D., at this year's MauiDerm: Advances in Cosmetic and Medical Dermatology. Approved for primary axillary hyperhidrosis in January 2011, the miraDry System (Miramar Labs) essentially kills targeted sweat glands with microwave energy."

Sentinel lymph node (SLN) status represents the most important prognostic factor for disease-specific survival in primary cutaneous melanomas, said Christopher K. Bichakjian, M.D., at the 70th annual meeting of the American Academy of Dermatology. However, he says, its impact on overall survival remains unclear.

Although hardly unexpected, the Food and Drug Administration's decision to add a warning about a possible link between tumor necrosis factor (TNF) antagonists and cancer in children goes too far, say most dermatologists contacted by Dermatology Times.

National report - Experts disagree on the possible impact a new pediatric cancer warning for tumor necrosis factor (TNF) inhibitors may have on this drug category's growth.